{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:38:57Z","timestamp":1780393137129,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clinme.2024.100250","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T04:43:49Z","timestamp":1728017029000},"page":"100250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Individualised therapeutic approach to the patient with atypical haemolytic-uraemic syndrome"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8033-9482","authenticated-orcid":false,"given":"Ivana","family":"Mika\u010di\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolina","family":"Mari\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinme.2024.100250_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: state of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clinme.2024.100250_sbref0002","series-title":"StatPearls","article-title":"Hemolytic uremic syndrome","author":"Bhandari","year":"2023"},{"key":"10.1016\/j.clinme.2024.100250_bib0003","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/IJNRD.S215370","article-title":"Optimal management of atypical hemolytic uremic disease: challenges and solutions","volume":"12","author":"Raina","year":"2019","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"12","key":"10.1016\/j.clinme.2024.100250_bib0004","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualised complement blockade has revolutionised clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinme.2024.100250_bib0005","series-title":"Pediatric Allergy: Principles and Practice","article-title":"Biologic therapies","author":"Eisenberg","year":"2016"},{"issue":"9","key":"10.1016\/j.clinme.2024.100250_bib0006","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-021-05370-8","article-title":"Thrombotic microangiopathy in children","volume":"37","author":"Palma","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"10095","key":"10.1016\/j.clinme.2024.100250_sbref0007","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinme.2024.100250_bib0008","unstructured":"European Medicines Agency, EMA\/785583\/2011 - soliris: committee for medicinal products for human use (CHMP). https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/soliris-h-c-791-ii-0027-epar-assessment-report-variation_en.pdf (accessed 4 March 2024)."},{"key":"10.1016\/j.clinme.2024.100250_bib0009","unstructured":"Medicines Law & Policy series of briefing documents, European Union Review of Pharmaceutical Incentives: Suggestions for Change. https:\/\/medicineslawandpolicy.org\/wp-content\/uploads\/2019\/06\/European-Union-Review-of-Pharma-Incentives-Introduction-and-Summary.pdf (accessed 10 June 2024)."},{"issue":"6","key":"10.1016\/j.clinme.2024.100250_bib0010","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1542\/peds.2014-3503","article-title":"Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome","volume":"135","author":"Cullinan","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinme.2024.100250_bib0011","doi-asserted-by":"crossref","unstructured":"R. Levy, P. Chen, K. Johnston, Y. Wang, E. Popoff, I. Tomazos, I, Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome, J Med Econ. 25(1) 249\u2013259. https:\/\/doi.org\/10.1080\/13696998.2022.2027706.","DOI":"10.1080\/13696998.2022.2027706"},{"key":"10.1016\/j.clinme.2024.100250_bib0012","unstructured":"European Medicines Agency, EMA\/114622\/2023 - Bekemv: committee for medicinal products for human use (CHMP). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/bekemv-epar-public-assessment-report_en.pdf (accessed 1 March 2024)."},{"key":"10.1016\/j.clinme.2024.100250_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/295323","article-title":"Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome","author":"Tsai","year":"2014","journal-title":"Adv Hematol"},{"issue":"2","key":"10.1016\/j.clinme.2024.100250_bib0014","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2007.03558.x","article-title":"Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis","volume":"151","author":"Noris","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"10.1016\/j.clinme.2024.100250_bib0015","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1681\/ASN.2010080795","article-title":"Allelic variants of complement genes associated with dense deposit disease","volume":"22","author":"Abrera-Abeleda","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"18","key":"10.1016\/j.clinme.2024.100250_bib0016","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clinme.2024.100250_sbref0017","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00467-018-4091-3","article-title":"Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use","volume":"34","author":"Wijnsma","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.clinme.2024.100250_bib0018","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialised service in England for atypical haemolytic uraemic syndrome-the first year's experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM: Monthly J Assoc Phys"},{"key":"10.1016\/j.clinme.2024.100250_bib0019","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2018.07.006","article-title":"Atypical hemolytic uremic syndrome: review of clinical presentation, diagnosis and management","volume":"461","author":"Sridharan","year":"2018","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.clinme.2024.100250_bib0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.clinme.2024.100250_bib0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10157-018-1609-8","article-title":"Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of postmarketing surveillance","volume":"23","author":"Kato","year":"2019","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"10.1016\/j.clinme.2024.100250_bib0022","first-page":"2","article-title":"Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis","volume":"14","author":"Laurence","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"issue":"6","key":"10.1016\/j.clinme.2024.100250_bib0023","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","article-title":"Therapeutic drug monitoring of eculizumab: rationale for an individualised dosing schedule","volume":"7","author":"Gatault","year":"2015","journal-title":"mAbs"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824054356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824054356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:46:42Z","timestamp":1732733202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824054356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1470211824054356"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2024.100250","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualised therapeutic approach to the patient with atypical haemolytic-uraemic syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2024.100250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100250"}}